Recombinant Human RAB9A Protein, N-His from ProteoGenix; catalogue ARO-P11671; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human RAB9A protein, also known as Ras-related protein Rab-9A, is a member of the Ras superfamily of small GTPases. It is involved in the regulation of intracellular vesicular trafficking and plays a crucial role in the transport of proteins between different compartments within the cell. This protein is highly conserved across species and is expressed in various tissues, including the brain, heart, kidney, and liver.
The human RAB9A protein is composed of 204 amino acids with a molecular weight of approximately 23 kDa. It contains a conserved GTPase domain, which is responsible for its GTP binding and hydrolysis activity. This domain is flanked by N-terminal and C-terminal regions, which play a role in protein-protein interactions and membrane targeting, respectively.
RAB9A also contains a polybasic region, which is important for its interaction with phospholipids on the membrane surface. Additionally, it has a C-terminal prenylation motif, which is essential for its membrane localization and function.
RAB9A is an important regulator of intracellular vesicular trafficking, specifically in the late endosomal/lysosomal pathway. It is involved in the transport of cargo proteins from the trans-Golgi network to the late endosomes and from the late endosomes to the lysosomes. This process is crucial for the maintenance of cellular homeostasis and proper functioning of the endocytic pathway.
RAB9A functions as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. In its active form, it interacts with effector proteins, such as the retromer complex, which is involved in the retrograde transport of proteins from the endosomes to the Golgi. RAB9A also regulates the fusion of late endosomes with lysosomes, which is essential for the degradation of internalized material.
Mutations in the RAB9A gene have been linked to the development of neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. These mutations disrupt the protein’s normal function, leading to impaired vesicular transport and accumulation of toxic proteins in the cells.
Recombinant Human RAB9A protein has various applications in both basic research and drug development. It can be used to study the mechanisms of intracellular trafficking and its role in disease pathogenesis. It can also be used to investigate the function of RAB9A in different cell types and tissues, as well as its interactions with other proteins and signaling pathways.
Furthermore, RAB9A has been identified as a potential therapeutic target for neurodegenerative diseases. Modulation of its activity could potentially restore normal vesicular transport and prevent the accumulation of toxic proteins in the cells. Recombinant RAB9A protein can be used in drug screening assays to identify small molecules that can modulate its activity and potentially serve as novel treatments for these diseases.
In addition, recombinant RAB9A protein can be used in the production of antibodies for diagnostic and research purposes. It can also be used as an antigen in immunization studies to generate specific antibodies against the protein, which can then be used to study its localization and function in different cellular contexts.
Recombinant Human RAB9A protein is a key player in the regulation of intracellular vesicular trafficking and is essential for maintaining cellular homeostasis. Its structure, activity, and application have been extensively studied and continue to be a subject of research in the field of cell biology and disease pathogenesis. With its potential as a therapeutic target and its use in various research applications, RAB9A
ProteoGenix catalogue number ARO-P11671. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 23.36 kDa; Fragment: Met1-Asp186; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
